For nearly a century, if you wanted to invest in a high-flying tech startup before it went public, first you had to answer a simple question: "Are you a millionaire?" If the answer was no, the SEC labeled you a "non-accredited” investor — and you were locked out of the deal.…
In the old days, if you’d told me you’d invested in a startup, I’d have asked the obvious question: “When do you think it’ll IPO?” That was the dream. The startup would grow, go public, and your small investment could turn into a big sum.
I’ve got three “Hot Zombies” for you this week. As I noted last week, venture capitalists are throwing billions of dollars into a tiny handful of elite AI and defense giants.
A few years ago, a buddy of mine from business school invited me to a fancy dinner at his Manhattan brownstone. By the time I finished my first glass of Champagne, I’d met most of the guests — a mix of money managers, venture capitalists, and private equity heavyweights.
While the world obsesses over the next AI model, a quieter but equally ambitious race is underway: the race to slow, stop, or reverse aging itself. This market is called longevity biotech, and billions of investment dollars are pouring into it.